Alzheimer’s Drug Donanemab Shows Promise in Slowing Disease Progression Introduction A major clinical trial has revealed that the Alzheimer’s drug donanemab, developed by US pharmaceutical giant Eli Lilly, can slow down the rate of cognitive decline in patients. Although it is not a cure, the results offer hope that this therapy could one day halt […]
Drug Donanemab Seen as Turning Point in Dementia Fight A new drug called donanemab is being hailed as a turning point in the fight against Alzheimer’s disease, after a global trial confirmed its ability to slow cognitive decline. The antibody medicine works by clearing a protein that builds up in the brains of people with […]
